文献速递真菌感染

新型多曲霉属逆转录定量PCR的临床验证:诊断性病例对照研究

Clinical validation of a new multi-Aspergillus species reverse transcriptase quantitative PCR: a diagnostic case-control study.
PubMed 文献 · Clin Microbiol Infect · 2026-03-28

该诊断性病例对照研究设计、优化并验证了一种基于逆转录定量PCR的多曲霉属检测方法(MAS-RTqPCR),可检测六个曲霉属section的全核酸。在120例患者223份血浆样本中,临床敏感性0.91(95% CI 0.71-0.98),特异性1.00(95% CI 0.93-1.00)。该检测有望用于侵袭性曲霉病的诊断和PCR阳性患者监测。

要点

  • MAS-RTqPCR检测限为5拷贝/反应,分析特异性100%。
  • 临床敏感性0.91,特异性1.00,基于120例患者223份血浆样本。
  • 随访显示MAS-RTqPCR优于参考检测,并可检出非烟曲霉感染。

核心结论

  • MAS-RTqPCR是侵袭性曲霉病有前景的诊断工具,并可用于监测PCR阳性患者。

研究设计与样本

  • 诊断性病例对照研究,设计、优化并验证基于逆转录定量PCR的多曲霉属section特异性引物检测方法。
  • 检测六个曲霉属section(Fumigati、Flavi、Nigri、Terrei、Nidulantes、Usti)的全核酸。
  • 使用三组患者共120例和223份血浆样本进行临床验证。

主要发现

  • 检测限为5拷贝/反应,基于>90种真菌物种筛查的分析特异性为100%。
  • 临床敏感性0.91(95% CI 0.71-0.98),临床特异性1.00(95% CI 0.93-1.00)。
  • 对阳性患者随访显示MAS-RTqPCR优于参考检测。
  • MAS-RTqPCR检出3例非烟曲霉感染患者。

临床怎么用

  • 可考虑将MAS-RTqPCR用于侵袭性曲霉病的诊断及PCR阳性患者的随访监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Invasive aspergillosis is a difficult-to-diagnose fungal disease, the diagnosis of which relies on many criteria including mycological criteria. Recently, the European Organisation for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium promoted Aspergillus PCR as a specific marker given the significant progress made in optimizing and standardizing Aspergillus real-time quantitative PCR (qPCR) assays. However, there is no unique and optimal assay in the literature, particularly for optimally detecting aspergillosis due to the main Aspergillus species responsible for invasive aspergillosis. METHODS: We therefore designed, optimized, and validated a new type of real-time PCR assay using a diagnostic case-control study approach. This assay is based on reverse transcriptase qPCR methodology and multi-Aspergillus section-specific primers (multi Aspergillus species reverse transcriptase qPCR [MAS-RTqPCR]). This assay detects whole nucleic acids from species belonging to six Aspergillus sections (Fumigati, Flavi, Nigri, Terrei, Nidulantes, and Usti). RESULTS: The limit of detection of this assay was five copies per reaction, and the analytical specificity was 100% based on the screening of >90 fungal species. We used three groups of patients to validate the assay, testing 120 patients and 223 plasma samples. The clinical sensitivity was 0.91 (95% CI, 0.71-0.98) and clinical specificity was 1.00 (95% CI, 0.93-1.00). Follow-up of positive patients revealed superiority of the MAS-RTqPCR assay compared with the reference assay. In addition, our MAS-RTqPCR assay detected three patients with non-Aspergillus fumigatus infections. CONCLUSIONS: Overall, this study demonstrates that our MAS-RTqPCR assay is a promising diagnostic for invasive aspergillosis and monitoring PCR-positive patients.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Benazra M, Mallek W, Ghelfenstein-Ferreira T, et al. Clinical validation of a new multi-Aspergillus species reverse transcriptase quantitative PCR: a diagnostic case-control study. Clin Microbiol Infect. 2026. PMID: 41911972. doi:10.1016/j.cmi.2026.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。